Kooperativer Bibliotheksverbund

UID:

Format: XX, 335 S , graph. Darst

Series Statement: Annals of the New York Academy of Sciences 569

Language: Undetermined

UID:

Format: 1 Online-Ressource (xviii, 496 Seiten) , color illustrations

Edition: Third edition

ISBN: 1464805245 , 9781464805240

Series Statement: World Bank E-Library Archive

Content: Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.--

Note: Includes bibliographical references

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 9781464805240

Language: English

DOI: 10.1596/978-1-4648-0524-0

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (xxlii, 662 Seiten) : , Illustrationen, Diagramme, Karten.

Edition: Second edition

ISBN: 978-0-12-805400-0

Series Statement: ClinicalKey

Content: "The Vaccine Book, Second Edition provides comprehensive information on the current and future state of vaccines. It reveals the scientific opportunities and potential impact of vaccines, including economic and ethical challenges, problems encountered when producing vaccines, how clinical vaccine trials are designed, and how to introduce vaccines into widespread use. Although vaccines are now available for many diseases, there are still challenges ahead for major diseases, such as AIDS, tuberculosis, and malaria. This book is designed for students, researchers, public health officials, and all others interested in increasing their understanding of vaccines. It answers common questions regarding the use of vaccines in the context of a rapidly expanding anti-vaccine environment. This new edition is completely updated and revised with new and unique topics, including new vaccines, problems of declining immunization rates, trust in vaccines, the vaccine hesitancy, and the social value of vaccines for the community vs. the individual child's risk"--Publisher's description

Note: Revised edition of: The vaccine book / edited by Barry R. Bloom, Paul-Henri Lambert. ©2003. - Includes bibliographical references

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-0-12-802174-3

Language: English

DOI: 10.1016/C2014-0-00804-0

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 online resource (xiv, 637 pages) : , illustrations

Edition: Electronic reproduction. [S.l.] : HathiTrust Digital Library, 2010.

ISBN: 9781555818357 , 1555818358 , 9781555819101 , 1555819109 , 9781683672753 , 1683672755

Series Statement: Monograph, ASM Press

Note: Preface -- INTRODUCTION TO TUBERCULOSIS -- ANIMAL MODELS OF TUBERCULOSIS -- GENETICS OF MYCOBACTERIUM TUBERCULOSIS -- PHYSIOLOGY OF MYCOBACTERIUM TUBERCULOSIS -- V. IMMUNOLOGY AND PATHOGENESIS OF TUBERCULOSIS -- NEW APPROACHES TO PREVENTION AND TREATMENT OF Tuberculosis -- Index. , Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.

Additional Edition: Print version: Tuberculosis. Washington, D.C. : ASM Press, ©1994 ISBN 1555810721

Language: English

Keywords: Electronic books. ; Electronic books. ; Electronic books.

DOI: 10.1128/9781555818357

URL: https://onlinelibrary.wiley.com/doi/book/10.1128/9781555818357

URL: https://onlinelibrary.wiley.com/doi/book/10.1128/9781555818357

URL: https://onlinelibrary.wiley.com/doi/book/10.1128/9781555818357

UID:

Format: XXIX, 748 S. 8"

Language: Undetermined

UID:

Format: XXIV, 578 S. mit Abb. 8"

Language: Undetermined

UID:

Format: XXIV, 578 S. : , Ill., graph. Darst.

ISBN: 0-12-107760-8 , 0-12-107750-0

Language: English

Subjects: Biology , Medicine

Keywords: Zelluläre Immunität ; Konferenzschrift

UID:

Format: 1 online resource (734 PDF pages) : , illustrations, maps, graphs

ISBN: 9780128054000 (e-book)

Additional Edition: Print version: Vaccine book. Amsterdam, [Netherlands] : Academic Press, 2016, c2003 ISBN 9780128021743

Language: English

Keywords: Electronic books. ; Electronic books.

URL: Click to View

URL: Click to View

UID:

Format: 1 online resource

Edition: 2nd ed.

ISBN: 0-12-805400-X

Note: Intro -- Title page -- Table of Contents -- Copyright -- Dedication -- Contributors -- Preface -- Introduction-Global Burden of Disease addressed by Current Vaccines and Vaccines in the Development Pipeline -- Part I: Understanding Vaccine Impact at Population and Individual Levels -- Chapter 1: The Impact of Vaccination on the Epidemiology of Infectious Diseases -- Abstract -- 1. Introduction -- 2. Changing world -- 3. Basic epidemiological principles -- 4. Vaccine coverage required to interrupt transmission -- 5. A shifting average age at infection -- 6. Perverse effects of vaccination -- 7. Troughs in herd immunity as a consequence of the introduction of cohort based vaccination -- 8. Indirect and direct effects of vaccination-benefits of herd immunity -- 9. Health economics-costs and benefits of vaccination -- 10. Partially effective vaccines-efficacy versus duration of protection -- 11. Spatial and other heterogeneities -- 12. Natural selection and mass vaccination -- 13. Discussion -- Chapter 2: How Vaccines Work -- Abstract -- 1. Introduction -- 2. What follows a vaccine injection? Basis of antibody response to protein vaccines -- 3. Vaccine antigen recognition -- 4. Germinal center reaction -- 5. Building B-cell memory -- 6. Response to polysaccharide vaccines -- 7. Vaccine-induced T-cell responses -- 8. Innate immunity and T-cell differentiation -- 9. Vaccine-induced T-cell memory -- 10. Conclusions -- Part II: How to Design, Assess and Produce Vaccines -- Chapter 3: Vaccine Design in the 21st Century -- Abstract -- 1. Introduction -- 2. Strategies for modern vaccine design -- 3. Conclusions and future outlook -- Acknowledgments -- Chapter 4: Vaccine Adjuvants -- Abstract -- 1. Brief adjuvant history -- 2. Adjuvants in current approved vaccines -- 3. Adjuvant development -- 4. Mechanisms of action -- 5. Formulation. , 6. Adjuvants for unmet needs -- HIV and tuberculosis vaccines -- Chapter 5: Vaccine Production: Main Steps and Considerations -- Abstract -- 1. Manufacturing basics -- 2. Considerations for manufacturing vaccines -- 3. Vaccine challenges from the industry perspective -- 4. Manufacturing dilemmas -- Acknowledgments -- Chapter 6: How are Vaccines Assessed in Clinical Trials? -- Summary -- 1. The vaccine testing paradigm -- 2. Ethical issues -- 3. Good Clinical Practices -- 4. Phase 1 -- 5. Phase 2 -- 6. Phase 3 -- 7. Issues to be considered in designing a Phase 3 vaccine efficacy trial -- 8. Phase 4 surveillance and studies to monitor product safety and the impact on disease burden with vaccine use post-licensure -- 9. Summary note -- Chapter 7: Immunological Correlates of Vaccine-Mediated Protection -- Abstract -- 1. Introduction -- 2. Definitions -- 3. Indentifying correlates of protection -- 4. Statistical methods for evaluating correlates of protection -- 5. Correlates of protection as effector or pathway correlates -- 6. Known correlates of protection for vaccines -- 7. Conclusions -- Part III: Vaccine Safety -- Chapter 8: How Vaccine Safety is Monitored -- Abstract -- 1. Introduction -- 2. Vaccine development -- 3. Investigational new drug (IND) application -- 4. Clinical trials -- 5. Regulatory approval -- 6. Vaccine recommendations -- 7. Postmarketing surveillance and special studies -- 8. Standardized case definitions -- 9. Clinical assessment and individual-level causality assessment -- 10. Compensation for vaccine injuries -- 11. Coordination -- 12. Investigations of reports of MMR and autism: an example -- 13. Summary -- Chapter 9: Vaccination and Autoimmune Diseases -- Abstract -- 1. Introduction -- 2. Understanding infection-associated autoimmunity -- 3. The risk of vaccine-associated autoimmunity. , 4. Vaccine-attributable autoimmune diseases -- 5. Allegations of autoimmune adverse effects -- 6. New generation vaccines and autoimmunity: approaches toward early risk assessment -- 7. Vaccination in patients with chronic autoimmune diseases -- 8. Conclusions -- Part IV: New Vaccination Strategies -- Chapter 10: Maternal Immunization: Protecting Vulnerable Populations -- Abstract -- 1. Introduction -- 2. Background -- 3. Vaccines currently administered to pregnant women -- 4. Potential maternal vaccines -- 5. Safety of maternal immunization -- 6. Potential obstacles for maternal immunization -- 7. Clinical trial designs -- 8. Social and ethical issues -- 9. Summary -- Chapter 11: New Challenges for Pertussis Vaccines -- Abstract -- 1. Historical perspective -- 2. Changing epidemiology -- 3. Current use of pertussis vaccines -- 4. Relative merits of acellular and whole-cell pertussis vaccines -- 5. Remaining gaps in control of pertussis -- 6. Prospects for new pertussis vaccines -- 7. Interim measures for the control of pertussis -- 8. Summary and conclusions -- Part V: Recently Introduced Vaccines -- Chapter 12: Pneumococcus, Pneumococcal Disease, and Prevention -- Abstract -- 1. Introduction -- 2. The organism and associated pathology -- 3. Epidemiology of pneumococcal disease -- 4. Immunology -- 5. Vaccines against pneumococcus -- 6. Future vaccine approaches -- 7. Conclusions -- Chapter 13: Human Papillomavirus Vaccines -- Abstract -- 1. Introduction -- 2. Burden of HPV-associated disease -- 3. HPV vaccines: rationale -- 4. Licensed prophylactic HPV vaccines -- 5. Vaccine efficacy -- 6. Implementation and effectiveness -- 7. Vaccine impact -- 8. Vaccine-induced immune responses -- 9. Safety -- 10. Alternative dosage schedules -- 11. Concluding remarks -- Chapter 14: Rotavirus Vaccines -- Abstract -- 1. Biology of rotavirus. , 2. Rotavirus disease and treatment -- 3. Burden and epidemiology of rotavirus -- 4. Rationale for rotavirus vaccine development -- 5. The first licensed rotavirus vaccine-Rotashield -- 6. Current internationally licensed rotavirus vaccines-Rotarix™ and RotaTeq -- 7. Remaining issues and challenges for rotavirus vaccines -- 8. Conclusions -- Disclaimer -- Part VI: New Approaches for Needed Vaccines -- Chapter 15: Antiviral Vaccines: Challenges and Advances -- Abstract -- 1. Introduction -- 2. Types of currently licensed antiviral vaccines -- 3. How antiviral vaccines mediate protection? -- 4. Modern approaches to studying immune responses induced by antiviral vaccines -- 5. Next generation vaccine platforms -- 6. Harnessing the technological advances to develop vaccines against challenging and emerging viruses -- 7. Summary -- Acknowledgments -- Chapter 16: New Approaches for Needed Vaccines: Bacteria -- Abstract -- 1. Background -- 2. Gaps and targets -- 3. Classical approaches for making bacterial vaccines -- 4. The impact of genomics on bacterial vaccine development -- 5. Reverse vaccinology -- 6. Live vaccines against bacteria -- 7. Vaccines based on membrane complexes -- 8. Killed oral vaccines -- 9. Bioconjugates -- 10. Concluding remarks -- Acknowledgment -- Chapter 17: Vaccines Against Parasites -- Abstract -- 1. Vaccination against malaria -- 2. Vaccination against leishmaniasis -- 3. Vaccination against helminths -- Part VII: Major Global Vaccine Challenges -- Chapter 18: Tuberculosis Vaccines -- Abstract -- 1. Introduction -- 2. Tuberculosis -- 3. The current TB vaccine - BCG -- 4. New strategies toward vaccination against TB -- Acknowledgments -- Chapter 19: Major Global Vaccine Challenges: Recent Progress in Malaria Vaccine Development -- Abstract -- 1. Introduction -- 2. Preerythrocytic vaccine candidates. , 3. Blood-stage vaccine candidates -- 4. Sexual stage vaccine candidates -- 5. Multiple-stage vaccine candidates -- 6. Vaccine candidates against malaria in pregnancy -- 7. P. vivax vaccine development status -- 8. Conclusions -- Acknowledgment -- Chapter 20: AIDS Vaccines -- Abstract -- 1. Introduction -- 2. Immune responses to HIV: what is needed? -- 3. Efficacy trials of candidate vaccines -- 4. Planned efficacy trials of candidate HIV vaccines -- 5. New HIV vaccine concepts on the horizon -- 6. Vaccines and the HIV cure agenda -- 7. Conclusions -- Chapter 21: Influenza Vaccines and Vaccination Strategies -- Abstract -- 1. Introduction -- 2. The influenza virus -- 3. Influenza disease and burden of illness -- 4. Influenza vaccines -- 5. Non-replicating influenza vaccines -- 6. Safety of non-replicating vaccines -- 7. Immunogenicity of inactivated vaccines -- 8. Efficacy and effectiveness -- 9. Populations of interest -- 10. Live-attenuated influenza vaccines (LAIVs) -- 11. Immunogenicity -- 12. Safety -- 13. Efficacy and effectiveness -- 14. Influenza vaccines in development -- 15. Vaccination policy and programs -- 16. Challenges of influenza vaccine programs in low resource settings -- 17. Summary -- Part VIII: Ethical Considerations -- Chapter 22: Ethical Considerations in Vaccine Trials in Resource-Limited Settings -- Abstract -- 1. Introduction -- 2. Ethical considerations -- 3. Conclusions -- Acknowledgment -- Part IX: Vaccine Economics -- Chapter 23: Economic Considerations for the Development of Global Vaccines: a Perspective From the Vaccine Industry -- Abstract -- 1. Program valuation and portfolio management -- 2. Conclusions -- Chapter 24: Introduction of Vaccines Into National Programs -- Abstract -- 1. Introduction -- 2. Political considerations -- 3. Natural history and epidemiologic considerations -- 4. Regulatory considerations. , 5. Program Considerations.

Additional Edition: ISBN 0-12-802174-8

Language: English

UID:

Format: 1 online resource

Edition: 2nd ed.

ISBN: 0-12-805400-X

Note: Intro -- Title page -- Table of Contents -- Copyright -- Dedication -- Contributors -- Preface -- Introduction-Global Burden of Disease addressed by Current Vaccines and Vaccines in the Development Pipeline -- Part I: Understanding Vaccine Impact at Population and Individual Levels -- Chapter 1: The Impact of Vaccination on the Epidemiology of Infectious Diseases -- Abstract -- 1. Introduction -- 2. Changing world -- 3. Basic epidemiological principles -- 4. Vaccine coverage required to interrupt transmission -- 5. A shifting average age at infection -- 6. Perverse effects of vaccination -- 7. Troughs in herd immunity as a consequence of the introduction of cohort based vaccination -- 8. Indirect and direct effects of vaccination-benefits of herd immunity -- 9. Health economics-costs and benefits of vaccination -- 10. Partially effective vaccines-efficacy versus duration of protection -- 11. Spatial and other heterogeneities -- 12. Natural selection and mass vaccination -- 13. Discussion -- Chapter 2: How Vaccines Work -- Abstract -- 1. Introduction -- 2. What follows a vaccine injection? Basis of antibody response to protein vaccines -- 3. Vaccine antigen recognition -- 4. Germinal center reaction -- 5. Building B-cell memory -- 6. Response to polysaccharide vaccines -- 7. Vaccine-induced T-cell responses -- 8. Innate immunity and T-cell differentiation -- 9. Vaccine-induced T-cell memory -- 10. Conclusions -- Part II: How to Design, Assess and Produce Vaccines -- Chapter 3: Vaccine Design in the 21st Century -- Abstract -- 1. Introduction -- 2. Strategies for modern vaccine design -- 3. Conclusions and future outlook -- Acknowledgments -- Chapter 4: Vaccine Adjuvants -- Abstract -- 1. Brief adjuvant history -- 2. Adjuvants in current approved vaccines -- 3. Adjuvant development -- 4. Mechanisms of action -- 5. Formulation. , 6. Adjuvants for unmet needs -- HIV and tuberculosis vaccines -- Chapter 5: Vaccine Production: Main Steps and Considerations -- Abstract -- 1. Manufacturing basics -- 2. Considerations for manufacturing vaccines -- 3. Vaccine challenges from the industry perspective -- 4. Manufacturing dilemmas -- Acknowledgments -- Chapter 6: How are Vaccines Assessed in Clinical Trials? -- Summary -- 1. The vaccine testing paradigm -- 2. Ethical issues -- 3. Good Clinical Practices -- 4. Phase 1 -- 5. Phase 2 -- 6. Phase 3 -- 7. Issues to be considered in designing a Phase 3 vaccine efficacy trial -- 8. Phase 4 surveillance and studies to monitor product safety and the impact on disease burden with vaccine use post-licensure -- 9. Summary note -- Chapter 7: Immunological Correlates of Vaccine-Mediated Protection -- Abstract -- 1. Introduction -- 2. Definitions -- 3. Indentifying correlates of protection -- 4. Statistical methods for evaluating correlates of protection -- 5. Correlates of protection as effector or pathway correlates -- 6. Known correlates of protection for vaccines -- 7. Conclusions -- Part III: Vaccine Safety -- Chapter 8: How Vaccine Safety is Monitored -- Abstract -- 1. Introduction -- 2. Vaccine development -- 3. Investigational new drug (IND) application -- 4. Clinical trials -- 5. Regulatory approval -- 6. Vaccine recommendations -- 7. Postmarketing surveillance and special studies -- 8. Standardized case definitions -- 9. Clinical assessment and individual-level causality assessment -- 10. Compensation for vaccine injuries -- 11. Coordination -- 12. Investigations of reports of MMR and autism: an example -- 13. Summary -- Chapter 9: Vaccination and Autoimmune Diseases -- Abstract -- 1. Introduction -- 2. Understanding infection-associated autoimmunity -- 3. The risk of vaccine-associated autoimmunity. , 4. Vaccine-attributable autoimmune diseases -- 5. Allegations of autoimmune adverse effects -- 6. New generation vaccines and autoimmunity: approaches toward early risk assessment -- 7. Vaccination in patients with chronic autoimmune diseases -- 8. Conclusions -- Part IV: New Vaccination Strategies -- Chapter 10: Maternal Immunization: Protecting Vulnerable Populations -- Abstract -- 1. Introduction -- 2. Background -- 3. Vaccines currently administered to pregnant women -- 4. Potential maternal vaccines -- 5. Safety of maternal immunization -- 6. Potential obstacles for maternal immunization -- 7. Clinical trial designs -- 8. Social and ethical issues -- 9. Summary -- Chapter 11: New Challenges for Pertussis Vaccines -- Abstract -- 1. Historical perspective -- 2. Changing epidemiology -- 3. Current use of pertussis vaccines -- 4. Relative merits of acellular and whole-cell pertussis vaccines -- 5. Remaining gaps in control of pertussis -- 6. Prospects for new pertussis vaccines -- 7. Interim measures for the control of pertussis -- 8. Summary and conclusions -- Part V: Recently Introduced Vaccines -- Chapter 12: Pneumococcus, Pneumococcal Disease, and Prevention -- Abstract -- 1. Introduction -- 2. The organism and associated pathology -- 3. Epidemiology of pneumococcal disease -- 4. Immunology -- 5. Vaccines against pneumococcus -- 6. Future vaccine approaches -- 7. Conclusions -- Chapter 13: Human Papillomavirus Vaccines -- Abstract -- 1. Introduction -- 2. Burden of HPV-associated disease -- 3. HPV vaccines: rationale -- 4. Licensed prophylactic HPV vaccines -- 5. Vaccine efficacy -- 6. Implementation and effectiveness -- 7. Vaccine impact -- 8. Vaccine-induced immune responses -- 9. Safety -- 10. Alternative dosage schedules -- 11. Concluding remarks -- Chapter 14: Rotavirus Vaccines -- Abstract -- 1. Biology of rotavirus. , 2. Rotavirus disease and treatment -- 3. Burden and epidemiology of rotavirus -- 4. Rationale for rotavirus vaccine development -- 5. The first licensed rotavirus vaccine-Rotashield -- 6. Current internationally licensed rotavirus vaccines-Rotarix™ and RotaTeq -- 7. Remaining issues and challenges for rotavirus vaccines -- 8. Conclusions -- Disclaimer -- Part VI: New Approaches for Needed Vaccines -- Chapter 15: Antiviral Vaccines: Challenges and Advances -- Abstract -- 1. Introduction -- 2. Types of currently licensed antiviral vaccines -- 3. How antiviral vaccines mediate protection? -- 4. Modern approaches to studying immune responses induced by antiviral vaccines -- 5. Next generation vaccine platforms -- 6. Harnessing the technological advances to develop vaccines against challenging and emerging viruses -- 7. Summary -- Acknowledgments -- Chapter 16: New Approaches for Needed Vaccines: Bacteria -- Abstract -- 1. Background -- 2. Gaps and targets -- 3. Classical approaches for making bacterial vaccines -- 4. The impact of genomics on bacterial vaccine development -- 5. Reverse vaccinology -- 6. Live vaccines against bacteria -- 7. Vaccines based on membrane complexes -- 8. Killed oral vaccines -- 9. Bioconjugates -- 10. Concluding remarks -- Acknowledgment -- Chapter 17: Vaccines Against Parasites -- Abstract -- 1. Vaccination against malaria -- 2. Vaccination against leishmaniasis -- 3. Vaccination against helminths -- Part VII: Major Global Vaccine Challenges -- Chapter 18: Tuberculosis Vaccines -- Abstract -- 1. Introduction -- 2. Tuberculosis -- 3. The current TB vaccine - BCG -- 4. New strategies toward vaccination against TB -- Acknowledgments -- Chapter 19: Major Global Vaccine Challenges: Recent Progress in Malaria Vaccine Development -- Abstract -- 1. Introduction -- 2. Preerythrocytic vaccine candidates. , 3. Blood-stage vaccine candidates -- 4. Sexual stage vaccine candidates -- 5. Multiple-stage vaccine candidates -- 6. Vaccine candidates against malaria in pregnancy -- 7. P. vivax vaccine development status -- 8. Conclusions -- Acknowledgment -- Chapter 20: AIDS Vaccines -- Abstract -- 1. Introduction -- 2. Immune responses to HIV: what is needed? -- 3. Efficacy trials of candidate vaccines -- 4. Planned efficacy trials of candidate HIV vaccines -- 5. New HIV vaccine concepts on the horizon -- 6. Vaccines and the HIV cure agenda -- 7. Conclusions -- Chapter 21: Influenza Vaccines and Vaccination Strategies -- Abstract -- 1. Introduction -- 2. The influenza virus -- 3. Influenza disease and burden of illness -- 4. Influenza vaccines -- 5. Non-replicating influenza vaccines -- 6. Safety of non-replicating vaccines -- 7. Immunogenicity of inactivated vaccines -- 8. Efficacy and effectiveness -- 9. Populations of interest -- 10. Live-attenuated influenza vaccines (LAIVs) -- 11. Immunogenicity -- 12. Safety -- 13. Efficacy and effectiveness -- 14. Influenza vaccines in development -- 15. Vaccination policy and programs -- 16. Challenges of influenza vaccine programs in low resource settings -- 17. Summary -- Part VIII: Ethical Considerations -- Chapter 22: Ethical Considerations in Vaccine Trials in Resource-Limited Settings -- Abstract -- 1. Introduction -- 2. Ethical considerations -- 3. Conclusions -- Acknowledgment -- Part IX: Vaccine Economics -- Chapter 23: Economic Considerations for the Development of Global Vaccines: a Perspective From the Vaccine Industry -- Abstract -- 1. Program valuation and portfolio management -- 2. Conclusions -- Chapter 24: Introduction of Vaccines Into National Programs -- Abstract -- 1. Introduction -- 2. Political considerations -- 3. Natural history and epidemiologic considerations -- 4. Regulatory considerations. , 5. Program Considerations.

Additional Edition: ISBN 0-12-802174-8

Language: English